{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:21:52Z","timestamp":1784193712787,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11523-025-01187-9","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:27:39Z","timestamp":1764746859000},"page":"37-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-4244","authenticated-orcid":false,"given":"Erick F.","family":"Saldanha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana M.","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C. A.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Robson Costa","family":"Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbert O. C.","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anelise P.","family":"Cappellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Felipe Costa","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Henri","family":"Maselli-Shoueri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Diego Holanda","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio F.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"1187_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","volume":"11","author":"BA Krantz","year":"2017","unstructured":"Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279\u201389.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1187_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1187_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","volume":"20","author":"RD Carvajal","year":"2023","unstructured":"Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20(2):99\u2013115.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1187_CR4","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","volume":"11","author":"PA Johansson","year":"2020","unstructured":"Johansson PA, Brooks K, Newell F, Palmer JM, Wilmott JS, Pritchard AL, et al. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nat Commun. 2020;11(1):2408.","journal-title":"Nat Commun"},{"issue":"7","key":"1187_CR5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","volume":"51","author":"AH Shain","year":"2019","unstructured":"Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, et al. The genetic evolution of metastatic uveal melanoma. Nat Genet. 2019;51(7):1123\u201330.","journal-title":"Nat Genet"},{"issue":"7","key":"1187_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","volume":"134","author":"CL Decatur","year":"2016","unstructured":"Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728\u201333.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"1187_CR7","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370\u201380.","journal-title":"Ann Oncol"},{"issue":"3","key":"1187_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS ONE. 2015;10(3):e0118564.","journal-title":"PLoS ONE"},{"issue":"4","key":"1187_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","volume":"25","author":"AM Joshua","year":"2015","unstructured":"Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015;25(4):342\u20137.","journal-title":"Melanoma Res"},{"key":"1187_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","volume":"119","author":"P Nathan","year":"2019","unstructured":"Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;119:168\u201378.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1187_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Alonso Carrion L, Martin-Algarra S, et al. Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586\u201398.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1187_CR12","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256\u201366.","journal-title":"N Engl J Med"},{"issue":"13","key":"1187_CR13","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"11","key":"1187_CR14","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","volume":"28","author":"RD Carvajal","year":"2022","unstructured":"Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med. 2022;28(11):2364\u201373.","journal-title":"Nat Med"},{"issue":"1","key":"1187_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2374647","volume":"20","author":"Y Dian","year":"2024","unstructured":"Dian Y, Liu Y, Zeng F, Sun Y, Deng G. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis. Hum Vaccin Immunother. 2024;20(1):2374647.","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"1187_CR16","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.31557\/APJCP.2025.26.7.2267","volume":"26","author":"MM AlBarakat","year":"2025","unstructured":"AlBarakat MM, Wadaa-Allah A, Altawalbeh RB, Hamam KM, Tarawneh DY, Al Momani A, et al. Efficacy and safety of tebentafusp in uveal melanoma: a systematic review and single-arm meta-analysis. Asian Pac J Cancer Prev. 2025;26(7):2267\u201375.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1187_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2398870","volume":"20","author":"M Shabil","year":"2024","unstructured":"Shabil M, Bushi G, Rai N, Abu Serhan H. Comment on: \u201cEfficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis.\u201d Hum Vaccin Immunother. 2024;20(1):2398870.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1187_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104496","volume":"10","author":"EF Saldanha","year":"2025","unstructured":"Saldanha EF, Ribeiro MF, Hirsch I, Spreafico A, Saibil SD, Butler MO. How we treat patients with metastatic uveal melanoma. ESMO Open. 2025;10(4):104496.","journal-title":"ESMO Open"},{"issue":"1","key":"1187_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111.","journal-title":"BMC Med Res Methodol"},{"key":"1187_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009028","author":"JJ Sacco","year":"2024","unstructured":"Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, et al. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009028.","journal-title":"J Immunother Cancer"},{"issue":"22","key":"1187_CR21","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, et al. Tebentafusp, a TCR\/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869\u201378.","journal-title":"Clin Cancer Res"},{"key":"1187_CR22","doi-asserted-by":"publisher","first-page":"S742","DOI":"10.1016\/j.annonc.2024.08.1197","volume":"35","author":"P Nathan","year":"2024","unstructured":"Nathan P, Tharakan JN, Sacco JJ, Proudfoot-Jones J, Furness A, McMahon DJ, et al. Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM). Ann Oncol. 2024;35:S742\u20133.","journal-title":"Ann Oncol"},{"key":"1187_CR23","doi-asserted-by":"publisher","first-page":"S679","DOI":"10.1016\/j.annonc.2023.09.2265","volume":"34","author":"MF Ribeiro","year":"2023","unstructured":"Ribeiro MF, Hirsch I, Koch EC, Mantle L, Pimentel Muniz T, Silveira Vilbert M, et al. 1131P management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting. Ann Oncol. 2023;34:S679.","journal-title":"Ann Oncol"},{"key":"1187_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.020","author":"GJ Riew","year":"2025","unstructured":"Riew GJ, Hijaz BA, Haq R, Chen ST, LeBoeuf NR, Shi CR. Severity and progression of dermatologic adverse events associated with tebentafusp: a retrospective multicenter cohort study. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.020.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1187_CR25","doi-asserted-by":"publisher","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","volume":"15","author":"M Rodrigues","year":"2024","unstructured":"Rodrigues M, Ramtohul T, Rampanou A, Sandoval JL, Houy A, Servois V, et al. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp. Nat Commun. 2024;15(1):8851.","journal-title":"Nat Commun"},{"issue":"16_suppl","key":"1187_CR26","doi-asserted-by":"publisher","first-page":"e21533","DOI":"10.1200\/JCO.2025.43.16_suppl.e21533","volume":"43","author":"E Rossi","year":"2025","unstructured":"Rossi E, Di Guardo L, Simeone E, Giannarelli D, Pigozzo J, Marconcini R, et al. Tebentafusp in metastatic uveal melanoma patients: results of the Italian expanded access program. J Clin Oncol. 2025;43(16_suppl):e21533\u2013e21533.","journal-title":"J Clin Oncol"},{"key":"1187_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133430","author":"D Tomsitz","year":"2023","unstructured":"Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, et al. Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15133430.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1187_CR28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaad.2024.08.037","volume":"91","author":"D Tomsitz","year":"2024","unstructured":"Tomsitz D, Kerl K, French LE, Heinzerling L. Clinical and pathological characterization of tebentafusp-associated skin toxicity: a cohort study with 33 patients. J Am Acad Dermatol. 2024;91(6):1136\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"1187_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115634","volume":"227","author":"MK van der Kooij","year":"2025","unstructured":"van der Kooij MK, Kapiteijn E, Rutkowski P, Baurain JF, de Koning L, Speetjens FM, et al. Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN expert centres. Eur J Cancer. 2025;227:115634.","journal-title":"Eur J Cancer"},{"key":"1187_CR30","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.41297","volume":"104","author":"L Vitek","year":"2024","unstructured":"Vitek L, Goronflot T, Dutriaux C, Deleuze A, Le Corre Y, Duval-Modeste AB, et al. Efficacy and tolerability of tebentafusp in metastatic uveal melanoma: a real-life retrospective multicentre study. Acta Derm Venereol. 2024;104:adv41297.","journal-title":"Acta Derm Venereol"},{"issue":"17","key":"1187_CR31","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1200\/JCO.21.01805","volume":"40","author":"RD Carvajal","year":"2022","unstructured":"Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol. 2022;40(17):1939\u201348.","journal-title":"J Clin Oncol"},{"key":"1187_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101408","volume":"20","author":"T Olivier","year":"2022","unstructured":"Olivier T, Prasad V. Tebentafusp in first-line melanoma trials: an outperforming outlier. Transl Oncol. 2022;20:101408.","journal-title":"Transl Oncol"},{"key":"1187_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100156","volume":"5","author":"EF Saldanha","year":"2024","unstructured":"Saldanha EF, Nicolo E, Venetis K, de Miguel-Perez D, Ortega-Franco A, Dipasquale A, et al. The role of liquid biopsy as a catalyst for sustained progress in precision oncology\u2014perspective of the young committee of the international society of liquid biopsy. J Liq Biopsy. 2024;5:100156.","journal-title":"J Liq Biopsy"},{"key":"1187_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104776","volume":"213","author":"R Borea","year":"2025","unstructured":"Borea R, Saldanha EF, Maheswaran S, Nicolo E, Singhal S, Pontolillo L, et al. Cancer in a drop: advances in liquid biopsy in 2024. Crit Rev Oncol Hematol. 2025;213:104776.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1187_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1078-0432.CCR-22-0028","volume":"29","author":"DM Berman","year":"2023","unstructured":"Berman DM, Bell JI. Redirecting polyclonal T cells against cancer with soluble T-cell receptors. Clin Cancer Res. 2023;29(4):697\u2013704.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1187_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1172\/JCI181464","volume":"135","author":"R Staeger","year":"2025","unstructured":"Staeger R, Tastanova A, Ghosh A, Winkelbeiner N, Shukla P, Kolm I, et al. Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients. J Clin Invest. 2025;135(12):17.","journal-title":"J Clin Invest"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01187-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01187-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01187-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:47:03Z","timestamp":1771692423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01187-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01187-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Erick F. Saldanha, Mariana M. Noronha, Pedro C.A. Reis, Pedro Robson Costa Passos, Valbert O.C. Filho, Anelise P. Cappellaro, Luiz Felipe Costa Almeida, Jean Henri Maselli-Shoueri, Carlos Diego Holanda Lopes, Luis F. Leite da Silva, Mauricio F. Ribeiro, and Daniel V. Araujo declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish"}},{"value":"The data supporting the findings of this study are available upon reasonable request from the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Erick Saldanha: conceptualization, data curation, methodology, writing\u2014original draft preparation, and writing\u2014reviewing and editing. Mariana Noronha: conceptualization, data curation, methodology, and writing\u2014original draft preparation. Pedro Reis: methodology. Pedro Passos: methodology. Valbert Filho: methodology. Anelise P. Cappellaro: data curation. Luiz Felipe Almeida: data curation. Luis Felipe L. da Silva: data curation. Jean Maselli-Shoueri: data curation. Carlos Diego Lopes: supervision. Mauricio Ribeiro: visualization, supervision, and writing\u2014reviewing and editing. Daniel Araujo: visualization, supervision, and writing\u2014reviewing and editing.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}